Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert J Carpenter is Director at Immuneering. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 11, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
ImmuneeringIMRX
Jun 11, 202633K
DetailsOfficial recordRobert J Carpenter bought shares on the open market in 2021, and has not bought since 2021.
Robert J Carpenter reported 1 open-market purchase and 0 sales since 2021; purchases in 2021.
| Year | Bought | Sold |
|---|---|---|
| 2021 | $4.88M1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Robert J Carpenter bought shares on the open market in 2021, and has not bought since 2021.
In SEC filings since 2021: the latest open-market purchase is from 2021; no open-market sale is on record.
Immuneering (IMRX), from 2021 to 2021: 1 purchase and 0 sales.
Robert J Carpenter reported 1 open-market purchase and 0 sales here, 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.